Proprietary AI analyst is now available
- Public Comps
- Jiangxi Fushine Pharma
Jiangxi Fushine Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Jiangxi Fushine Pharma and similar public comparables like Liaoning Chengda Biotech, Chongqing Genrix, Sawai Group Holdings, Mezzion Pharma and more.
Jiangxi Fushine Pharma Overview
About Jiangxi Fushine Pharma
Jiangxi Fushine Pharmaceutical Co Ltd is engaged in research and development, manufactures and sells APIs and pharmaceutical intermediates. It offers penicillin, carbapenem, and other products.
Founded
2002
HQ

Employees
N/A
Website
Financials (LTM)
EV
$1B
Valuation Multiples
Start free trialJiangxi Fushine Pharma Financials
Jiangxi Fushine Pharma reported last 12-month revenue of $250M and EBITDA of $78M.
In the same LTM period, Jiangxi Fushine Pharma generated $96M in gross profit, $78M in EBITDA, and $40M in net income.
Revenue (LTM)
Jiangxi Fushine Pharma P&L
In the most recent fiscal year, Jiangxi Fushine Pharma reported revenue of $183M and EBITDA of $25M.
Jiangxi Fushine Pharma is unprofitable as of last fiscal year, with gross margin of 16%, EBITDA margin of 14%, and net margin of (3%).
Financial data powered by Morningstar, Inc.
Jiangxi Fushine Pharma Stock Performance
Jiangxi Fushine Pharma has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Jiangxi Fushine Pharma's stock price is $2.33.
Jiangxi Fushine Pharma share price increased by 3.4% in the last 30 days, and by 78.7% in the last year.
Jiangxi Fushine Pharma has an EPS (earnings per share) of $-0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | -1.7% | 3.4% | -12.4% | 78.7% | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialJiangxi Fushine Pharma Valuation Multiples
Jiangxi Fushine Pharma trades at 5.7x EV/Revenue multiple, and 18.2x EV/EBITDA.
EV / Revenue (LTM)
Jiangxi Fushine Pharma Financial Valuation Multiples
As of June 5, 2026, Jiangxi Fushine Pharma has market cap of $1B and EV of $1B.
Jiangxi Fushine Pharma has a P/E ratio of 31.3x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Jiangxi Fushine Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Jiangxi Fushine Pharma Margins & Growth Rates
Jiangxi Fushine Pharma grew revenue by 86% and EBITDA by 516% in the last fiscal year.
In the most recent fiscal year, Jiangxi Fushine Pharma reported gross margin of 16%, EBITDA margin of 14%, and net margin of (3%).
Jiangxi Fushine Pharma Margins
Jiangxi Fushine Pharma Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Jiangxi Fushine Pharma Operational KPIs
Jiangxi Fushine Pharma's Rule of 40 is 140% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jiangxi Fushine Pharma's Rule of X is 281% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Jiangxi Fushine Pharma Competitors
Jiangxi Fushine Pharma competitors include Liaoning Chengda Biotech, Chongqing Genrix, Sawai Group Holdings, Mezzion Pharma, Eczacıbaşı İlaç, Chengdu Easton, Harrow, Neuren Pharma, Everest Medicines and Avalyn Pharma.
Most Jiangxi Fushine Pharma public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.5x | 2.6x | 9.9x | 11.3x | |||
| 32.4x | 19.6x | (17.2x) | - | |||
| 1.4x | 1.3x | 7.6x | 7.5x | |||
| 247.0x | - | (53.8x) | - | |||
| 6.0x | - | 12.3x | - | |||
| 5.1x | 4.8x | 17.1x | 17.0x | |||
| 5.5x | 4.9x | 24.2x | 21.9x | |||
| 21.9x | 20.4x | 56.7x | 68.5x | |||
This data is available for Pro users. Sign up to see all Jiangxi Fushine Pharma competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Jiangxi Fushine Pharma
| When was Jiangxi Fushine Pharma founded? | Jiangxi Fushine Pharma was founded in 2002. |
| Where is Jiangxi Fushine Pharma headquartered? | Jiangxi Fushine Pharma is headquartered in China. |
| Is Jiangxi Fushine Pharma publicly listed? | Yes, Jiangxi Fushine Pharma is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Jiangxi Fushine Pharma? | Jiangxi Fushine Pharma trades under 300497 ticker. |
| When did Jiangxi Fushine Pharma go public? | Jiangxi Fushine Pharma went public in 2015. |
| Who are competitors of Jiangxi Fushine Pharma? | Jiangxi Fushine Pharma main competitors include Liaoning Chengda Biotech, Chongqing Genrix, Sawai Group Holdings, Mezzion Pharma, Eczacıbaşı İlaç, Chengdu Easton, Harrow, Neuren Pharma, Everest Medicines, Avalyn Pharma. |
| What is the current market cap of Jiangxi Fushine Pharma? | Jiangxi Fushine Pharma's current market cap is $1B. |
| What is the current revenue of Jiangxi Fushine Pharma? | Jiangxi Fushine Pharma's last 12 months revenue is $250M. |
| What is the current revenue growth of Jiangxi Fushine Pharma? | Jiangxi Fushine Pharma revenue growth (NTM/LTM) is 54%. |
| What is the current EV/Revenue multiple of Jiangxi Fushine Pharma? | Current revenue multiple of Jiangxi Fushine Pharma is 5.7x. |
| What is the current EBITDA of Jiangxi Fushine Pharma? | Jiangxi Fushine Pharma's last 12 months EBITDA is $78M. |
| What is Jiangxi Fushine Pharma's EBITDA margin? | Jiangxi Fushine Pharma's last 12 months EBITDA margin is 31%. |
| What is the current EV/EBITDA multiple of Jiangxi Fushine Pharma? | Current EBITDA multiple of Jiangxi Fushine Pharma is 18.2x. |
| How many companies Jiangxi Fushine Pharma has acquired to date? | Jiangxi Fushine Pharma hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Jiangxi Fushine Pharma has invested to date? | Jiangxi Fushine Pharma hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Jiangxi Fushine Pharma
Lists including Jiangxi Fushine Pharma
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.